<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153422</url>
  </required_header>
  <id_info>
    <org_study_id>212029</org_study_id>
    <nct_id>NCT04153422</nct_id>
  </id_info>
  <brief_title>IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS or FGFR-3 Antibodies</brief_title>
  <official_title>Intravenous Immunoglobulin (IVIG) in the Treatment of Autoimmune Small Fiber Neuropathy Due to TS-HDS and FGFR-3 Antibodies: a Double Blinded Placebo-controlled Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll patients with small fiber neuropathy (SFN). The study will look at an&#xD;
      intravenous immunoglobulin (IVIG) called Gammagard. Gammagard is approved by the FDA as a&#xD;
      therapy for certain diseases that result from an impaired immune system and as a maintenance&#xD;
      therapy to improve sensation and strength in patients with Chronic Immune Demyelinating&#xD;
      Polyneuropathy (CIDP) and muscle strength in adults with Multifocal Motor Neuropathy (MMN).&#xD;
      It has not been approved by the FDA for use in this condition.&#xD;
&#xD;
      There is mounting evidence that Intravenous Immunoglobulin (IVIG) can cause pain reduction&#xD;
      and improve objective nerve fiber densities on skin biopsies in great numbers in SFN&#xD;
      patients. The primary outcome is quantified improvement in intraepidermal nerve fiber density&#xD;
      (IENFD) on repeat skin punch biopsy after 6 months of IVIG treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Small fiber neuropathy (SFN) is an increasingly prevalent diagnosis in neurology and&#xD;
      neuromuscular centers. Modern diagnostic techniques, including skin biopsies and autonomic&#xD;
      nervous testing, are helping to find SFN in many patients with undiagnosed pain syndromes&#xD;
      including even fibromyalgia. The prevalence is rising for SFN, and an immune etiology may&#xD;
      underlie up to 20% of cases. There is mounting evidence that Intravenous Immunoglobulin&#xD;
      (IVIG) can cause pain reduction and improve objective nerve fiber densities on skin biopsies&#xD;
      in great numbers in SFN patients. They would be spared the side effects of steroids. But&#xD;
      neither IVIG nor any other immunosuppressant has been studied in a randomized clinical trial&#xD;
      to demonstrate efficacy. Trisulfated disaccharide IdoA2S-GlcNS-6S (TS-HDS) and fibroblast&#xD;
      growth factor receptor 3 (FGFR-3) serum antibodies are novel antibodies being discovered in&#xD;
      large numbers of otherwise cryptogenic SFN cases. The hypothesis of this double-blinded&#xD;
      placebo-controlled Phase II trial is that IVIG is effective in improving biopsies as a&#xD;
      primary endpoint, and in improving pain, SFN symptom and disability scales, objective&#xD;
      neuropathy physical exam scores, and antibody titers as secondary endpoints. Given the&#xD;
      demonstrated prevalence of SFN and especially this novel autoimmune syndrome, this trial&#xD;
      could have impact on thousands of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Recruitment not started at Loyola, PI leaving Loyola, PI may resume at next affiliating&#xD;
    instituation.&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled design with 10 patients in the treatment arm and 10 in the placebo arm. Patients in the treatment arm will receive 2g/kg Gammagard IVIG initially (1g/kg dose on Day 1 and 1g/kg dose on Day 2) and then 1g/kg maintenance infusions for 5 additional months (six months total). Patients in the placebo arm will receive 0.9% NaCl during the initial infusion and at maintenance infusions for 5 additional months (six months total).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a double-blind trial. The participant and the investigator will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>quantified change in intraepidermal nerve fiber density (IENFD)</measure>
    <time_frame>Week 24</time_frame>
    <description>3mm skin punch biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in visual analogue pain scale responses</measure>
    <time_frame>baseline and Week 28</time_frame>
    <description>Self-reported pain intensity on a scale of 0-10 using the Wong-Baker FACES Pain Rating Scale, with 0 being no pain and 10 being pain as bad as can be</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Small Fiber Neuropathy-Rasch Overall Disability Scale (SFN-RODS) score</measure>
    <time_frame>baseline and Week 28</time_frame>
    <description>The SFN-RODS is a 32-item scale measuring disability in daily activities. Scores range from 0 - 64, with a lower score correlating with worse disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Small Fiber Neuropathy-Symptom Inventory Questionnaire (SFN-SIQ) score</measure>
    <time_frame>baseline and Week 28</time_frame>
    <description>The SFN-SIQ is a validated 13-item scale measuring various SFN and autonomic symptoms. Scores range from 0 -39, with a higher score correlating with more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Small Fiber Neuropathy-Screening List (SFN-SL) score</measure>
    <time_frame>baseline and Week 28</time_frame>
    <description>The SFN-SL is a validated 21 item scale measuring frequency and severity of SFN and autonomic symptoms. Scores range from 0 - 84, with higher scores reflecting increased disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Utah Early Neuropathy Scale (UENS) examination scores</measure>
    <time_frame>baseline and Week 28</time_frame>
    <description>The UENS is a validated physical exam score from 0-42 points to look for small fiber neuropathy. It includes measures of sensation, reflexes, and strength in both lower extremities. A higher score indicates increased impairment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Small Fiber Neuropathy</condition>
  <condition>Autoimmune Small Fiber Neuropathy</condition>
  <condition>Inflammatory Polyneuropathy</condition>
  <condition>Immune-Mediated Neuropathy</condition>
  <arm_group>
    <arm_group_label>Treatment (IVIG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the treatment arm will receive 2g/kg Gammagard IVIG initially (1g/kg dose on Day 1 and 1g/kg dose on Day 2) and then 1g/kg maintenance infusions for 5 additional months (six months total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the placebo arm will receive 0.9% NaCl during the initial infusion and at maintenance infusions for 5 additional months (six months total).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gammagard IVIG</intervention_name>
    <description>Immune Globulin Infusion 10% (Human)</description>
    <arm_group_label>Treatment (IVIG)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients â‰¥ age 18&#xD;
&#xD;
          2. Patient with clinical and biopsy evidence of pure small fiber neuropathy as evidenced&#xD;
             by reduced IENFD on skin biopsy using PGP 9.5 as the immunostain. Biopsy must have&#xD;
             been performed within 12 months of study enrollment.&#xD;
&#xD;
          3. Patients must have elevated titers of autoantibodies to TS-HDS-IgM or FGFR3-IgG,&#xD;
             measured by the Washington University Neuromuscular Laboratory (St Louis).&#xD;
&#xD;
          4. Patients must have a baseline pain score on a visual analogue scale (VAS) of Greater&#xD;
             or equal to 4/10&#xD;
&#xD;
          5. Patients must have a baseline Utah Early Neuropathy Scale (UENS) score of Greater or&#xD;
             equal to 4/10&#xD;
&#xD;
          6. Small Fiber Neuropathy Screening List (SFNSL) score of 11/84 or greater&#xD;
&#xD;
          7. Non-pregnant, non-lactating female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other known cause for small fiber neuropathy other than the presence of the&#xD;
             elevated titers of auto-antibodies.&#xD;
&#xD;
          2. Patients with generalized, severe musculoskeletal conditions other than SFN that&#xD;
             prevent a sufficient assessment of the patient by the physician.&#xD;
&#xD;
          3. Underlying severe heart, kidney, liver disease, or HIV infection,&#xD;
&#xD;
          4. Patients with a history of deep vein thrombosis within the last year prior to baseline&#xD;
             visit or pulmonary embolism ever; patients with susceptibility to embolism or deep&#xD;
             vein thrombosis.&#xD;
&#xD;
          5. Known IgA deficiency with antibodies to IgA,&#xD;
&#xD;
          6. History of hypersensitivity, anaphylaxis or severe systemic response to&#xD;
             immuno-globulin, blood or plasma derived products, or any component of Gammagard,&#xD;
&#xD;
          7. Known blood hyperviscosity, or other hypercoagulable states,&#xD;
&#xD;
          8. Use of IgG products within six months prior to enrollment,&#xD;
&#xD;
          9. Patients with a history of drug or alcohol abuse within the past five years prior to&#xD;
             enrollment,&#xD;
&#xD;
         10. Patients unable or unwilling to understand or comply with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Zeidman, MD, FAAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwest Community Healthcare</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Peters MJ, Bakkers M, Merkies IS, Hoeijmakers JG, van Raak EP, Faber CG. Incidence and prevalence of small-fiber neuropathy: a survey in the Netherlands. Neurology. 2013 Oct 8;81(15):1356-60. doi: 10.1212/WNL.0b013e3182a8236e. Epub 2013 Aug 30.</citation>
    <PMID>23997150</PMID>
  </reference>
  <reference>
    <citation>Antoine JC, Boutahar N, LassabliÃ¨re F, Reynaud E, Ferraud K, Rogemond V, Paul S, Honnorat J, CamdessanchÃ© JP. Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1347-55. doi: 10.1136/jnnp-2014-309730. Epub 2015 Jan 27.</citation>
    <PMID>25628376</PMID>
  </reference>
  <reference>
    <citation>Pestronk A, Schmidt RE, Choksi RM, Sommerville RB, Al-Lozi MT. Clinical and laboratory features of neuropathies with serum IgM binding to TS-HDS. Muscle Nerve. 2012 Jun;45(6):866-72. doi: 10.1002/mus.23256.</citation>
    <PMID>22581541</PMID>
  </reference>
  <reference>
    <citation>Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006 May;46(5):741-53. Review.</citation>
    <PMID>16686841</PMID>
  </reference>
  <reference>
    <citation>Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med. 2017 May;126:135-138. doi: 10.1016/j.rmed.2017.03.011. Epub 2017 Mar 9.</citation>
    <PMID>28318820</PMID>
  </reference>
  <reference>
    <citation>Singleton JR, Bixby B, Russell JW, Feldman EL, Peltier A, Goldstein J, Howard J, Smith AG. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst. 2008 Sep;13(3):218-27. doi: 10.1111/j.1529-8027.2008.00180.x.</citation>
    <PMID>18844788</PMID>
  </reference>
  <reference>
    <citation>Souayah N, Chin RL, Brannagan TH, Latov N, Green PH, Kokoszka A, Sander HW. Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol. 2008 Dec;15(12):1300-3. doi: 10.1111/j.1468-1331.2008.02305.x.</citation>
    <PMID>19049545</PMID>
  </reference>
  <reference>
    <citation>Iodice V, et al. Ganglionic Antibody Mediated SFN. Neurology 2009;72:2002-6.</citation>
  </reference>
  <reference>
    <citation>D'agostino, R. B., Chase, W., &amp; Belanger, A. (1988). The appropriateness of some common procedures for testing the equality of two independent binomial populations. The American Statistician, 42(3), 198-202.</citation>
  </reference>
  <reference>
    <citation>Fleiss, J. L., Levin, B., &amp; Paik, M. C. (2013). Statistical methods for rates and proportions. John Wiley &amp; Sons.</citation>
  </reference>
  <reference>
    <citation>Brouwer BA, Bakkers M, Hoeijmakers JG, Faber CG, Merkies IS. Improving assessment in small fiber neuropathy. J Peripher Nerv Syst. 2015 Sep;20(3):333-40. doi: 10.1111/jns.12128.</citation>
    <PMID>26114213</PMID>
  </reference>
  <reference>
    <citation>Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. Respir Med. 2011 Jan;105(1):95-100. doi: 10.1016/j.rmed.2010.09.014.</citation>
    <PMID>20889323</PMID>
  </reference>
  <reference>
    <citation>Hobson-Webb LD, Austin SL, Jain S, Case LE, Greene K, Kishnani PS. Small-fiber neuropathy in pompe disease: first reported cases and prospective screening of a clinic cohort. Am J Case Rep. 2015 Apr 3;16:196-201. doi: 10.12659/AJCR.893309.</citation>
    <PMID>25835646</PMID>
  </reference>
  <reference>
    <citation>Sun B, Li Y, Liu L, Chen Z, Ling L, Yang F, Liu J, Liu H, Huang X. SFN-SIQ, SFNSL and skin biopsy of 55 cases with small fibre involvement. Int J Neurosci. 2018 May;128(5):442-448. doi: 10.1080/00207454.2017.1398152. Epub 2017 Nov 21.</citation>
    <PMID>29077516</PMID>
  </reference>
  <reference>
    <citation>Liu X, Treister R, Lang M, Oaklander AL. IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. Ther Adv Neurol Disord. 2018 Jan 8;11:1756285617744484. doi: 10.1177/1756285617744484. eCollection 2018.</citation>
    <PMID>29403541</PMID>
  </reference>
  <reference>
    <citation>Levine TD, Kafaie J, Zeidman LA, Saperstein DS, Massaquoi R, Bland RJ, Pestronk A. Cryptogenic small-fiber neuropathies: Serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor receptor-3. Muscle Nerve. 2020 Apr;61(4):512-515. doi: 10.1002/mus.26748. Epub 2019 Nov 6.</citation>
    <PMID>31650561</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Lawrence Zeidman</investigator_full_name>
    <investigator_title>Medical Director, Neuromuscular Medicine, Northwest Community Healthcare; Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Small Fiber Neuropathy</keyword>
  <keyword>Neuropathy</keyword>
  <keyword>Intravenous Immunoglobulin</keyword>
  <keyword>IVIG</keyword>
  <keyword>Gammagard</keyword>
  <keyword>TS-HDS antibody</keyword>
  <keyword>FGFR-3 antibody</keyword>
  <keyword>FGFR3 antibody</keyword>
  <keyword>Immune mediated small fiber neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Small Fiber Neuropathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

